Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Income from Continuing Operations (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Income from Continuing Operations for 6 consecutive years, with 79118000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 3.63% year-over-year to 79118000.0, compared with a TTM value of 224801000.0 through Sep 2025, up 12.81%, and an annual FY2024 reading of 220662000.0, down 5.89% over the prior year.
  • Income from Continuing Operations was 79118000.0 for Q3 2025 at Autolus Therapeutics, down from 47917000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 26979000.0 in Q4 2022 and bottomed at 82094000.0 in Q3 2024.
  • Average Income from Continuing Operations over 4 years is 51476285.71, with a median of 46883000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations crashed 140.13% in 2023, then soared 57.39% in 2024.
  • Year by year, Income from Continuing Operations stood at 26979000.0 in 2022, then plummeted by 140.13% to 64786000.0 in 2023, then skyrocketed by 57.39% to 27605000.0 in 2024, then plummeted by 186.61% to 79118000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for AUTL at 79118000.0 in Q3 2025, 47917000.0 in Q2 2025, and 70161000.0 in Q1 2025.